Literature DB >> 24845658

Estimating the effectiveness in HIV prevention trials by incorporating the exposure process: application to HPTN 035 data.

Jingyang Zhang1, Elizabeth R Brown1,2.   

Abstract

Estimating the effectiveness of a new intervention is usually the primary objective for HIV prevention trials. The Cox proportional hazard model is mainly used to estimate effectiveness by assuming that participants share the same risk under the covariates and the risk is always non-zero. In fact, the risk is only non-zero when an exposure event occurs, and participants can have a varying risk to transmit due to varying patterns of exposure events. Therefore, we propose a novel estimate of effectiveness adjusted for the heterogeneity in the magnitude of exposure among the study population, using a latent Poisson process model for the exposure path of each participant. Moreover, our model considers the scenario in which a proportion of participants never experience an exposure event and adopts a zero-inflated distribution for the rate of the exposure process. We employ a Bayesian estimation approach to estimate the exposure-adjusted effectiveness eliciting the priors from the historical information. Simulation studies are carried out to validate the approach and explore the properties of the estimates. An application example is presented from an HIV prevention trial.
© 2014, The International Biometric Society.

Entities:  

Keywords:  HIV prevention; Hierarchical models; Intercourse; Markov chain Monte Carlo; Per‐exposure effectiveness; Zero‐inflated gamma

Mesh:

Substances:

Year:  2014        PMID: 24845658      PMCID: PMC4239192          DOI: 10.1111/biom.12183

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  22 in total

1.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

2.  Joint modeling of intercourse behavior and human fecundability using structural equation models.

Authors:  Sungduk Kim; Rajeshwari Sundaram; Germaine M Buck Louis
Journal:  Biostatistics       Date:  2010-02-19       Impact factor: 5.899

3.  Interpreting sexually transmissible infection prevention trials by adjusting for the magnitude of exposure.

Authors:  David P Wilson
Journal:  Clin Trials       Date:  2009-12-09       Impact factor: 2.486

4.  Sex acts, sex partners, and sex budgets: implications for risk factor analysis and estimation of HIV transmission probabilities.

Authors:  S M Blower; C Boe
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-12

5.  Per-contact risk of human immunodeficiency virus transmission between male sexual partners.

Authors:  E Vittinghoff; J Douglas; F Judson; D McKirnan; K MacQueen; S P Buchbinder
Journal:  Am J Epidemiol       Date:  1999-08-01       Impact factor: 4.897

6.  Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial.

Authors:  Lut Van Damme; Gita Ramjee; Michel Alary; Bea Vuylsteke; Verapol Chandeying; Helen Rees; Pachara Sirivongrangson; Léonard Mukenge-Tshibaka; Virginie Ettiègne-Traoré; Charn Uaheowitchai; Salim S Abdool Karim; Benoît Mâsse; Jos Perriëns; Marie Laga
Journal:  Lancet       Date:  2002-09-28       Impact factor: 79.321

7.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

8.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

9.  PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.

Authors:  Sheena McCormack; Gita Ramjee; Anatoli Kamali; Helen Rees; Angela M Crook; Mitzy Gafos; Ute Jentsch; Robert Pool; Maureen Chisembele; Saidi Kapiga; Richard Mutemwa; Andrew Vallely; Thesla Palanee; Yuki Sookrajh; Charles J Lacey; Janet Darbyshire; Heiner Grosskurth; Albert Profy; Andrew Nunn; Richard Hayes; Jonathan Weber
Journal:  Lancet       Date:  2010-09-17       Impact factor: 79.321

Review 10.  Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis.

Authors:  Kimberly A Powers; Charles Poole; Audrey E Pettifor; Myron S Cohen
Journal:  Lancet Infect Dis       Date:  2008-08-04       Impact factor: 25.071

View more
  1 in total

1.  Joint modeling of time-varying HIV exposure and infection for estimation of per-act efficacy in HIV prevention trials.

Authors:  Elizabeth R Brown; Clara P Dominguez Islas; Jingyang Zhang
Journal:  Stat Commun Infect Dis       Date:  2020-09-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.